# Mitazalimab

Source: https://onco.cc/drugs/mitazalimab/  
OnCo record `mitazalimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mitazalimab is a CD40 agonist antibody from Alligator Bioscience AB, in registered phase 2 trials for pancreatic ductal adenocarcinoma.

## Summary

Mitazalimab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Alligator Bioscience AB, in pancreatic ductal adenocarcinoma. It is a human CD40 agonistic IgG1 antibody, given with modified FOLFIRINOX in the OPTIMIZE-1 study (NCT04888312, Lancet Oncology 2024). OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: ADC-1013; JNJ-64457107
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Monoclonal antibody (CD40 agonist)
- Mechanism: A human IgG1 antibody that switches on CD40, the receptor on dendritic cells and macrophages that licenses them to prime T cells (OPTIMIZE-1, Lancet Oncology 2024). Despite the code ADC-1013 it is not an antibody-drug conjugate and carries no payload.

## Sources

- ClinicalTrials.gov: trials of Mitazalimab: https://clinicaltrials.gov/search?intr=Mitazalimab
- OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in metastatic pancreatic cancer (Lancet Oncology 2024): https://doi.org/10.1016/s1470-2045(24)00263-8

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [CD40](https://onco.cc/targets/cd40/)
- companies: [Alligator Bioscience](https://onco.cc/companies/alligator-bioscience/)
- trials: [Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer](https://onco.cc/trials/nct07199764/), [Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients](https://onco.cc/trials/nct04888312/)
- terms: [Tumour-associated macrophages (TAMs)](https://onco.cc/terms/tumor-associated-macrophages/)

---
JSON: https://onco.cc/api/v1/entities/mitazalimab.json